Video

Dr. Khaled on Recognition and Treatment of TA-TMA

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Samer K. Khaled, MD, medical director of hematology and HCT Clinical Operations at City of Hope, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy (TA-TMA).

The complication of TA-TMA occurs posttransplant, and patients with this condition often have a poor prognosis with an increase in mortality and morbidity. Therefore, Khaled suggests recognizing this condition early to begin treatment as soon as possible. Some data show that early treatment with a complement blockade can improve the outcomes for these patients, according to Khaled.

Research for treating TA-TMA is still in its early stages and the treatment procedure depends on the physician recognition of the condition, says Khaled. In the pediatric space, there are more efforts into systematically looking or screening for the markers of TA-TMA to recognize the complication early, concludes Khaled.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center